http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2131154-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 1993-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f5e13f008ade55427c431341ed2b4f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8d72d218239b0874d078f0a59b28f2f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab612ae4fe4c54ed1b8adf0302b3823 |
| publicationDate | 1993-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2131154-A1 |
| titleOfInvention | Antiviral peptides |
| abstract | Compounds of formula (I) and pharmaceutically acceptable salts thereof and bioprecursors therefore wherein R1 is C1-C6 alkyl, C3-C8 cycloalkyl, aryl, heterocyclyl or CONR9R10; R2 is C1-C6 alkyl, C3-C8 cycloalkyl(C1-C4)alkyl, aryl(C1-C4)alkyl or heterocyclyl(C1-C4)alkyl; R3 is C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C4)alkyl, aryl(C1-C4)alkyl, aryl(C2-C4)-alkenyl, heterocyclyl(C1-C4)alkyl or heterocyclyl(C2-C4)-alkenyl; R4 is C1-C6 alkyl, C3-C8 cycloalkyl, aryl or heterocyclyl; each of R5, R6, R7 and R8 is independently H, C1-C6 alkyl or C3-C8 cycloalkyl; or R5 and R6, or R7 and R8 may be joined together to form a 3 to 8 membered carbocyclic ring; X is a 4-10 membered mono or bicyclic heterocyclic group containing carbon ring atoms and one ring nitrogen atom through which the group is attached to the adjacent carbonyl group; the group may be saturated or partially unsaturated and, in addition to the -(CR7R8)m-Het substituent, it may be substituted by up to 4 further substituents independently chosen from F, C1-C6 alkyl, C3-C8 cycloalkyl, OR11 or NR9R10; Het is an imidazolyl or triazolyl group either of which may optionally be substituted by C1-C6 alkyl, C3-C7 cycloalkyl, NR9R10 or CONR9R10, each of R9 and R10 is independently H, C1-C6 alkyl or C3-C8 cycloalkyl, or R9 and R10 may be joined together to form, with the nitrogen to which they are attached, a 4 to 8 membered nitrogen-containing heterocyclic group, R11 is H, C1-C6 alkyl or C3-C8 cycloalkyl; n and m are each independently 0, 1 or 2; wherein any alkyl or cycloalkyl group included in the aforementioned definitions may optionally be fully or partially substituted by fluorine; are inhibitors of retroviral proteases of utility in the treatment and prophylaxis of human retroviral infections. |
| priorityDate | 1992-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 195.